The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $121,757.6 million in 2020.The Mexico was the fastest growing country, with a CAGR of 7% over the 2016-20 period.
- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $110,220.5 million in 2020. This was followed by Mexico and Canada, with a value of $6,202.9 and $5,334.3 million, respectively.
- The US is expected to lead the generics industry in the NAFTA bloc, with a value of $124,141.2 million in 2025, followed by Mexico and Canada with expected values of $7,892.1 and $5,938.8 million, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
- Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to Buy
- What was the size of the NAFTA generics market by value in 2020?
- What will be the size of the NAFTA generics market in 2025?
- What factors are affecting the strength of competition in the NAFTA generics market?
- How has the market performed over the last five years?
- How large is the NAFTA generics market in relation to its regional counterparts?
Table of Contents
1 Introduction1.1. What is this report about?1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA Generics2.1. Industry Outlook
3 Generics in Canada3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 Generics in Mexico4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 Generics in The United States5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 Company Profiles6.1. Pfizer Inc.
6.2. Teva Pharmaceutical Industries Limited
6.3. Apotex, Inc.
6.4. Viatris Inc.
6.5. Sun Pharmaceutical Industries Ltd
6.6. Aurobindo Pharma Ltd
7 Appendix7.1. Methodology
7.2. About the publisher
List of TablesTable 1: NAFTA countries generics industry, revenue ($m), 2016-25
Table 2: NAFTA countries generics industry, revenue ($m), 2016-20
Table 3: NAFTA countries generics industry forecast, revenue ($m), 2020-25
Table 4: Canada generics market value: $ million, 2016-20
Table 5: Canada generics market volume: %, 2016-20
Table 6: Canada generics market geography segmentation: $ million, 2020
Table 7: Canada generics market value forecast: $ million, 2020-25
Table 8: Canada generics market volume forecast: %, 2020-25
Table 9: Canada size of population (million), 2016-20
Table 10: Canada GDP (constant 2005 prices, $ billion), 2016-20
Table 11: Canada GDP (current prices, $ billion), 2016-20
Table 12: Canada inflation, 2016-20
Table 13: Canada consumer price index (absolute), 2016-20
Table 14: Canada exchange rate, 2016-20
Table 15: Mexico generics market value: $ million, 2016-20
Table 16: Mexico generics market volume: %, 2016-20
Table 17: Mexico generics market geography segmentation: $ million, 2020
Table 18: Mexico generics market value forecast: $ million, 2020-25
Table 19: Mexico generics market volume forecast: %, 2020-25
Table 20: Mexico size of population (million), 2016-20
Table 21: Mexico GDP (constant 2005 prices, $ billion), 2016-20
Table 22: Mexico GDP (current prices, $ billion), 2016-20
Table 23: Mexico inflation, 2016-20
Table 24: Mexico consumer price index (absolute), 2016-20
Table 25: Mexico exchange rate, 2016-20
Table 26: United States generics market value: $ billion, 2016-20
Table 27: United States generics market volume: %, 2016-20
Table 28: United States generics market geography segmentation: $ billion, 2020
Table 29: United States generics market value forecast: $ billion, 2020-25
Table 30: United States generics market volume forecast: %, 2020-25
Table 31: United States size of population (million), 2016-20
Table 32: United States GDP (constant 2005 prices, $ billion), 2016-20
Table 33: United States GDP (current prices, $ billion), 2016-20
Table 34: United States inflation, 2016-20
Table 35: United States consumer price index (absolute), 2016-20
Table 36: United States exchange rate, 2016-20
Table 37: Pfizer Inc.: key facts
Table 38: Pfizer Inc.: Annual Financial Ratios
Table 39: Pfizer Inc.: Key Employees
Table 40: Pfizer Inc.: Key Employees Continued
Table 41: Teva Pharmaceutical Industries Limited: key facts
Table 42: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 43: Teva Pharmaceutical Industries Limited: Key Employees
Table 44: Apotex, Inc.: key facts
Table 45: Apotex, Inc.: Key Employees
Table 46: Viatris Inc.: key facts
Table 47: Viatris Inc.: Annual Financial Ratios
Table 48: Viatris Inc.: Key Employees
Table 49: Sun Pharmaceutical Industries Ltd: key facts
Table 50: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 51: Sun Pharmaceutical Industries Ltd: Key Employees
Table 52: Aurobindo Pharma Ltd: key facts
Table 53: Aurobindo Pharma Ltd: Annual Financial Ratios
Table 54: Aurobindo Pharma Ltd: Key Employees
List of FiguresFigure 1: NAFTA countries generics industry, revenue ($m), 2016-25
Figure 2: NAFTA countries generics industry, revenue ($m), 2016-20
Figure 3: NAFTA countries generics industry forecast, revenue ($m), 2020-25
Figure 4: Canada generics market value: $ million, 2016-20
Figure 5: Canada generics market volume: %, 2016-20
Figure 6: Canada generics market geography segmentation: % share, by value, 2020
Figure 7: Canada generics market value forecast: $ million, 2020-25
Figure 8: Canada generics market volume forecast: %, 2020-25
Figure 9: Forces driving competition in the generics market in Canada, 2020
Figure 10: Drivers of buyer power in the generics market in Canada, 2020
Figure 11: Drivers of supplier power in the generics market in Canada, 2020
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2020
Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2020
Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2020
Figure 15: Mexico generics market value: $ million, 2016-20
Figure 16: Mexico generics market volume: %, 2016-20
Figure 17: Mexico generics market geography segmentation: % share, by value, 2020
Figure 18: Mexico generics market value forecast: $ million, 2020-25
Figure 19: Mexico generics market volume forecast: %, 2020-25
Figure 20: Forces driving competition in the generics market in Mexico, 2020
Figure 21: Drivers of buyer power in the generics market in Mexico, 2020
Figure 22: Drivers of supplier power in the generics market in Mexico, 2020
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2020
Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2020
Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2020
Figure 26: United States generics market value: $ billion, 2016-20
Figure 27: United States generics market volume: %, 2016-20
Figure 28: United States generics market geography segmentation: % share, by value, 2020
Figure 29: United States generics market value forecast: $ billion, 2020-25
Figure 30: United States generics market volume forecast: %, 2020-25
Figure 31: Forces driving competition in the generics market in the United States, 2020
Figure 32: Drivers of buyer power in the generics market in the United States, 2020
Figure 33: Drivers of supplier power in the generics market in the United States, 2020
Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2020
Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2020
Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- Apotex, Inc.
- Viatris Inc.
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Ltd
